A series of case reports from JEWELFISH, an open-label study to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of RG7916 in adult and pediatric patients with spinal muscular atrophy who previously participated in a study with another SMN2-targeting therapy

著录项

• 来源
  《Neuromuscular disorders: NMD》 |2017年第2期|共1页
• 作者

  Chiriboga C.; Mercuri E.; Fischer D.; Marquet A.; Kraus D.; Alexander M.; Cho A.; Armstrong G.; Kletzl H.; Czech C.; Seabrook T.; Abdallah H.; Mueller L.; Gorni K.; Khwaja O.;

  展开▼
• 作者单位

  Columbia Univ Ctr Med New York NY USA;

  Catholic Univ Rome Italy;

  Univ Basel Hosp Basel Switzerland;

  Roche Innovat Ctr Basel Switzerland;

  Roche Innovat Ctr Basel Switzerland;

  Roche Innovat Ctr New York New York NY USA;

  Roche Innovat Ctr New York New York NY USA;

  Roche Prod Ltd Welwyn Garden City Herts England;

  Roche Innovat Ctr Basel Switzerland;

  Roche Innovat Ctr Basel Switzerland;

  Roche Innovat Ctr Basel Switzerland;

  Roche Innovat Ctr Basel Switzerland;

  Roche Innovat Ctr Basel Switzerland;

  Roche Innovat Ctr Basel Switzerland;

  Roche Innovat Ctr Basel Switzerland;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 神经病学;
• 关键词